首页> 美国卫生研究院文献>Case Reports in Oncological Medicine >Metastases of Renal Cell Carcinoma to the Thyroid Gland with Synchronous Benign and Malignant Follicular Cell-Derived Neoplasms
【2h】

Metastases of Renal Cell Carcinoma to the Thyroid Gland with Synchronous Benign and Malignant Follicular Cell-Derived Neoplasms

机译:肾细胞癌向甲状腺转移的良性和恶性滤泡细胞同步性肿瘤的转移。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clear cell renal cell carcinoma (CCRCC) is the most common origin for metastasis in the thyroid. A 51-year-old woman was referred to our hospital for a subcarinal lesion. Ten years before, the patient had undergone a nephrectomy for CCRCC. Whole-body fluorodeoxyglucose positron emission tomography revealed elevated values in the thyroid gland, while the mediastinum was normal. An endoscopic ultrasonography-guided fine-needle aspiration biopsy of the mediastinal mass was consistent with CCRCC, and this was confirmed after resection. The thyroidectomy specimen also revealed lymphocytic thyroiditis, nodular hyperplasia, one follicular adenoma, two papillary microcarcinomas, and six foci of metastatic CCRCC involving both thyroid lobes. Curiously two of the six metastatic foci were located inside two adenomatoid nodules (tumor-in-tumor). The metastatic cells were positive for cytokeratins, CD10, epidermal growth factor receptor, and vascular endothelial growth factor receptor 2. No BRAF gene mutations were found in any of the primary and metastatic lesions. The patient was treated with sunitinib and finally died due to CCRCC distant metastases 6 years after the thyroidectomy. In CCRCC patients, a particularly prolonged survival rate may be achieved with the appropriate therapy, in contrast to the ominous prognosis typically found in patients with thyroid metastases from other origins.
机译:透明细胞肾细胞癌(CCRCC)是甲状腺转移的最常见起源。一名51岁的妇女因软骨下病变被转诊到我们医院。十年前,该患者因CCRCC接受了肾切除术。全身氟脱氧葡萄糖正电子发射断层扫描显示甲状腺中的值升高,而纵隔是正常的。内镜超声引导下纵隔肿块的细针穿刺活检与CCRCC一致,并且在切除后得到证实。甲状腺切除术标本还显示了淋巴细胞性甲状腺炎,结节性增生,1个滤泡性腺瘤,2个乳头状微癌和6个涉及两个甲状腺叶的转移性CCRCC灶。奇怪的是,六个转移灶中有两个位于两个腺瘤样结节(肿瘤内)中。转移细胞的细胞角蛋白,CD10,表皮生长因子受体和血管内皮生长因子受体2均为阳性。在任何原发性和转移性病变中均未发现BRAF基因突变。该患者接受舒尼替尼治疗,并因甲状腺切除术后6年CCRCC远处转移而死亡。在CCRCC患者中,通过适当的治疗可以实现特别延长的生存率,这与其他来源的甲状腺转移患者通常不祥的预后形成鲜明对比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号